FDA rejects Capricor's deramiocel application for Duchenne muscular dystrophy

On November 20, 2026, the U.S. FDA sent Capricor Therapeutics a Complete Response Letter rejecting the company's resubmitted application for deramiocel in Duchenne muscular dystrophy. The agency said the submission failed to demonstrate effectiveness and identified additional clinical deficiencies. Capricor said it disagrees with the assessment, maintains that its HOPE-2 and HOPE-3 studies met their primary endpoints, and is reviewing the letter before deciding its next steps.

The FDA decision prevents approval of Capricor's lead therapy on the current application and leaves the company facing an uncertain regulatory path. Capricor said it is reviewing the letter and its operating costs while assessing how to proceed.

  • 1The FDA issued the Complete Response Letter for Capricor's resubmitted Biologics License Application for deramiocel on November 20, 2026.
  • 2The agency said the application did not provide enough evidence to establish effectiveness and cited other clinical deficiencies.
  • 3Capricor said deramiocel had been evaluated in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, which it says both met their primary endpoints.
  • 4Capricor reported approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, which it believes can fund planned operations for at least the next 12 months.
  • 5Capricor scheduled a conference call and webcast for November 23 at 8:30 a.m. ET.
  • Reports give different declines for CAPR shares, ranging from 70% to 80%, and do not establish a common measurement time.
  • The materials do not disclose Capricor's timeline for responding to the FDA or resubmitting the application.

Sources